Sibel Naycı Sibel Naycı TIP FAKÜLTESİ DAHİLİ TIP BİLİMLERİ BÖLÜMÜ GÖĞÜS HASTALIKLARI ANABİLİM DALI
Araştırmacının yayınlarını daha detaylı bir şekilde aramak veya filtrelemek için buraya tıklayabilirsiniz.

Antifibrotic Treatment in Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF): Real-World outcomes from a Single-Center study

Polat Yuluğ, Demet | Televi, Beyza | Unal, Fatma Sevval | Sucu, Damla Hazal | Balci, Yuksel | Nayci, Sibel | Ozge, Cengiz | Ozgur, Eylem Sercan

Abstract Introduction: Antifibrotic therapies are widely used in both idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). We aim to compare the demographic, clinical characteristics, and long-term outcomes of IPF and PPF patients on antifibrotic treatment at 6-month and 1-year follow-ups. Methods and Materials: This was a retrospective single-center cohort study. Between January 2021 and January 2025, patients who initiated antifibrotic therapy were retrospectively included. Pulmonary function tests were recorded before treatment, at baseline, and at 6-month and 1-year follow-up visits. Additionally, baseline 6-minute walk test results and radiological data were also documented. Results: A total of 117 cases were included in the study, consisting of 76 IPF and 41 PPF. IPF patients were statistically significantly older than PPF patients (P < 0.001). The proportion of females was higher in the PPF group (P < 0.001). 52% of the cases used pirfenidone, while 48% used nintedanib. The most common subtype of PPF was connective tissue disease-associated ILD (48.8%), followed by nonspecific interstitial pneumonia (34.1%), and hypersensitivity pneumonitis (17.1%). In the PPF group, basal, 6-month, and 1-year follow-up FVC and DLCO values were statist...

Ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii: risk factors, clinical features, and outcomes

Ozgur, Eylem Sercan | Horasan, Şahin Elif | Ersöz, Gülden | Nayci Atış, Sibel | Kaya, Ali

Acinetobacter baumannii is characterized by a rapid development of resistance to the commonly used antimicrobial agents. We investigated the risk factors, clinical features, and outcomes in ventilatorassociated pneumonia (VAP) caused by extensive drug-resistant Acinetobacter baumannii (XDRAB). Clinical parameters and overall in-hospital mortality rates were compared between the VAP with and without XDRAB infection groups. This study showed that VAP caused by XDRAB was not associated with in-hospital mortality. However, it was related to high Simplified Acute Physiology Score II scores and increasing durations of hospital stays.